Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQDWMJ)

Drug Name
S-20928 Drug Info
Synonyms
152302-33-5; S-20928; N-(2-naphthalen-1-ylethyl)cyclobutanecarboxamide; N-(2-(1-Naphthalenyl)ethyl)cyclobutanecarboxamide; Cyclobutanecarboxamide,N-[2-(1-naphthalenyl)ethyl]-; ACMC-20n6et; AC1L2SR8; S 20928; CHEMBL12296; ZINC5833; GTPL1360; SCHEMBL6254856; CTK4C7390; DTXSID00164994; MolPort-009-303-106; GLXSBZGTGMPDKH-UHFFFAOYSA-N; AKOS030612657; MCULE-2771118083; N-[2-(1-naphthyl)ethyl]cyclobutanecarboxamide; S20928; n-[2-naphth-1-yl-ethyl]-cyclobutyl carboxamide; L000529; N-[2-(naphthalen-1-yl)ethyl]cyclobutanecarboxamide
Indication
Disease Entry ICD 11 Status REF
Sleep-wake disorder 7A00-7B2Z Terminated [1]
Cross-matching ID
PubChem CID
127856
CAS Number
CAS 152302-33-5
TTD Drug ID
DMQDWMJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Melatonin receptor type 1A (MTNR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [3]
Ramelteon DM7IW9J Insomnia 7A00-7A0Z Approved [4]
Tasimelteon DMLOQ1V Insomnia 7A00-7A0Z Approved [5]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [6]
LY-156735 DM5IX9M Anxiety disorder 6B00-6B0Z Phase 2 [7]
Agomelatine DMXYA5K Major depressive disorder 6A70.3 Withdrawn from market [8]
Luzindole DMXRJQV Sleep-wake disorder 7A00-7B2Z Terminated [9]
GR-133347 DMNRJA0 Anxiety disorder 6B00-6B0Z Terminated [10]
GR-131663 DMKAGLV Anxiety disorder 6B00-6B0Z Terminated [11]
SL-18.1616 DMI1WNF Insomnia 7A00-7A0Z Terminated [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melatonin receptor type 1A (MTNR1A) TT0WAIE MTR1A_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1360).
2 Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. J Pineal Res. 1998 Oct;25(3):172-6.
3 The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8.
4 MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288).
7 Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25.
8 Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68.
9 Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988 Sep;246(3):902-10.
10 US patent application no. 5,151,446, Substituted 2-amidotetralins as melatonin agonists and antagonists.
11 Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol. 1999 Oct 15;382(3):157-66.
12 US patent application no. 2005,016,4987, Melatonin combination therapy for improving sleep quality.